Peficitinib (hydrochloride)
Peficitinib (ASP015K) hydrochloride is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively[1].
Product Specifications
CAS Number
[1353219-06-3]
Product Name Alternative
ASP015K (hydrochloride) ; JNJ-54781532 (hydrochloride)
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/peficitinib-hydrochloride.html
Solubility
10 mM in DMSO
Smiles
O[C@](C[C@@H]1C[C@H]2C3)(C2)C[C@@H]3[C@H]1NC4=C5C(NC=C5)=NC=C4C(N)=O.Cl
Molecular Formula
C18H23ClN4O2
Molecular Weight
362.85
References & Citations
[1]Ito M, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017 Jan;133 (1) :25-33.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
JAK1; JAK2; JAK3; Tyk2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
F6401-01J-ML490 100 µL
FZD1, ID (Frizzled-1, Fz-1, hFz1, FzE1) (MaxLight 490) discontinued
Ask
View Details 
384967 100 µg
Alpha Synuclein (Alpha Synuclein, Non-A Beta Component Of AD Amyloid, Non-A4 Component Of Amyloid Precursor, NACP, SNCA, PARK1, PARK 1, AlphaSYN, PARK 4, PARK4, Parkinson Disease Familial 1, Parkinson Disease (Autosomal Dominant, Lewy Body) 4, SYN)
Ask
View Details